**uniQure N.V. Reports Fiscal Year 2025 Results**
uniQure N.V., a gene therapy company, released its financial results for the fiscal year ending December 31, 2025. The company reported total revenues of $16.1 million, a decrease of $11.0 million compared to the $27.1 million reported in 2024. This decline was primarily attributed to a $10.7 million decrease in collaboration revenues from CSL Behring, partially offset by a $5.8 million increase in license revenues. The company's net loss for 2025 was $199.0 million, a decrease of $40.6 million compared to the $239.6 million net loss in 2024.
Operating expenses for 2025 totaled $207.8 million, a decrease of $7.0 million from the $214.8 million reported in 2024. Research and development expenses decreased slightly to $140.7 million from $143.8 million in the previous year, while selling, general, and administrative expenses increased to $65.5 million from $52.7 million. The increase in selling, general, and administrative expenses was primarily due to higher personnel-related expenses incurred in preparation for a potential commercial launch of AMT-130 in the U.S. The company's cash and cash equivalents, restricted cash, and investment securities totaled $624.1 million as of December 31, 2025, compared to $367.5 million as of December 31, 2024.
Key operational developments included the ongoing clinical trials for AMT-130, AMT-260, AMT-191, and AMT-162. In September 2025, the company announced positive topline data from the pivotal Phase I/II study of AMT-130 for Huntington's disease. However, the FDA later indicated that the data was unlikely to support a BLA submission. The company also completed enrollment of the first cohort in the AMT-260 trial and initiated a second cohort. Enrollment continued in the AMT-191 trial, while enrollment in the AMT-162 trial was voluntarily paused.
In January 2025, uniQure completed a public offering, raising net proceeds of $80.5 million. In September 2025, the company completed another public offering, raising net proceeds of $323.7 million. The company also entered into a $175.0 million senior secured term loan facility with Hercules Capital in September 2025. The company anticipates that its existing cash and cash equivalents, restricted cash, and investment securities will be sufficient to fund its projected operating expenses into the second half of 2029.
About uniQure N.V.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.